JNJ vs. LLY, MRK, ABBV, PFE, BMY, ZTS, RPRX, JAZZ, PRGO, and CORT
Should you be buying Johnson & Johnson stock or one of its competitors? The main competitors of Johnson & Johnson include Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), AbbVie (ABBV), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceuticals" industry.
Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Johnson & Johnson has higher revenue and earnings than Eli Lilly and Company. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
In the previous week, Eli Lilly and Company had 27 more articles in the media than Johnson & Johnson. MarketBeat recorded 54 mentions for Eli Lilly and Company and 27 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.76 beat Eli Lilly and Company's score of 0.61 indicating that Johnson & Johnson is being referred to more favorably in the media.
Eli Lilly and Company received 88 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 70.09% of users gave Eli Lilly and Company an outperform vote while only 64.95% of users gave Johnson & Johnson an outperform vote.
Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.4%. Eli Lilly and Company pays an annual dividend of $5.20 per share and has a dividend yield of 0.6%. Johnson & Johnson pays out 30.9% of its earnings in the form of a dividend. Eli Lilly and Company pays out 76.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson is clearly the better dividend stock, given its higher yield and lower payout ratio.
Johnson & Johnson has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.
Johnson & Johnson currently has a consensus price target of $174.07, suggesting a potential upside of 19.19%. Eli Lilly and Company has a consensus price target of $787.53, suggesting a potential downside of 8.21%. Given Johnson & Johnson's higher probable upside, equities analysts clearly believe Johnson & Johnson is more favorable than Eli Lilly and Company.
Johnson & Johnson has a net margin of 45.26% compared to Eli Lilly and Company's net margin of 17.08%. Eli Lilly and Company's return on equity of 56.98% beat Johnson & Johnson's return on equity.
Summary
Johnson & Johnson beats Eli Lilly and Company on 11 of the 20 factors compared between the two stocks.
Get Johnson & Johnson News Delivered to You Automatically
Sign up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JNJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Johnson & Johnson Competitors List
Related Companies and Tools
